Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma

Both the combination of nivolumab + ipilimumab and single‐agent anti‐PD‐1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As the combination has a high rate of serious side effects, further analyses in randomized trials of combination versus anti‐PD‐1 immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosner, Samuel, Kwong, Erica, Shoushtari, Alexander N., Friedman, Claire F., Betof, Allison S., Brady, Mary Sue, Coit, Daniel G., Callahan, Margaret K., Wolchok, Jedd D., Chapman, Paul B., Panageas, Katherine S., Postow, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852343/
https://www.ncbi.nlm.nih.gov/pubmed/29468834
http://dx.doi.org/10.1002/cam4.1356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852343/
https://www.ncbi.nlm.nih.gov/pubmed/29468834
http://dx.doi.org/10.1002/cam4.1356

Ejemplares similares